Why is Concord Drugs falling/rising?

As of 08-Aug, Concord Drugs Ltd is experiencing a decline in its stock price, currently at 54.73, which reflects a decrease of 1.11 or 1.99%. The stock has underperformed its sector today by 0.83%. In terms of returns, over the past week, the stock has fallen by 2.27%, while it has shown a modest decline of 1.39% over the past month. However, on a year-to-date basis, the stock has performed exceptionally well, with a return of 44.03%, and a significant increase of 45.60% over the past year. The stock is currently trading above its 50-day, 100-day, and 200-day moving averages, but below its 5-day and 20-day moving averages. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 39.02% against the 5-day average, indicating a potential interest despite the current price drop. Unfortunately, there is no information available regarding specific positive or negative factors impacting the stock. In the broader market context, Concord Drugs' recent performance contrasts with the benchmark, the Sensex, which has declined by 0.92% over the past week and 4.60% over the past month. While the stock has underperformed in the short term compared to the benchmark, its strong year-to-date and yearly returns highlight its resilience and potential for recovery. The liquidity of the stock remains adequate for trading, suggesting that while the current price movement is downward, there is still sufficient market interest that could support future price stability or growth.